Nesopin ref. called 0.05% 20ml

Release form, composition and packaging

Nasal spray 0.05% in the form of a colorless or yellowish color, transparent or opalescent liquid.

1 ml

oxymetazoline hydrochloride 500 mcg

menthol, eucalyptus oil, disodium edetate, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, propylene glycol, benzyl alcohol, water d / i (up to 1 ml).

10 ml - polyethylene bottles (1) with a spray nozzle - cardboard packs.

20 ml - polyethylene bottles (1) with a spray nozzle - cardboard packs.

pharmachologic effect

Alpha-adrenergic agonist for topical use.

Has a vasoconstrictor effect.

With intranasal administration, the swelling of the mucous membrane of the upper respiratory tract decreases.

The action manifests itself 15 minutes after application and lasts for 8-12 hours.

Pharmacokinetics

Data on the pharmacokinetics of Nesopinne are provided.

Indications for use

- rhinitis (allergic and infectious-inflammatory etiology)

- sinusitis

- eustachitis

- hay fever.

Contraindications for use

- atrophic rhinitis

- pregnancy

- lactation period (breastfeeding)

- children under 6 years old

- hypersensitivity to drug components.

Care should be taken to prescribe the drug for chronic heart failure, arrhythmias, severe atherosclerosis, arterial hypertension, thyrotoxicosis, diabetes mellitus, chronic renal failure, angle-closure glaucoma.

Dosage regimen

Adults and children over 12 years of age are prescribed intranasally for 2-3 injections into each nasal passage with an interval of 10-12 hours.

Children from 6 to 12 years old - 1 injection into each nasal passage with an interval of 10-12 hours.

Overdose

Symptoms: tachycardia, increased blood pressure, depression of the central nervous system.

Treatment: symptomatic therapy is performed.

Side effect

Local reactions: transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing.

With prolonged use - tachyphylaxis, reactive hyperemia of the mucous membrane and atrophy of the mucous membrane of the nasal cavity.

Systemic reactions: increased blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disturbances.

Drug interactions

Slows down the absorption of local anesthetic drugs, lengthens their action.

The co-administration of other vasoconstrictor drugs increases the risk of side effects.

With the simultaneous appointment of MAO inhibitors and tricyclic antidepressants, an increase in blood pressure is possible.

Application during pregnancy and lactation

The drug is contraindicated for use during pregnancy and during breastfeeding.

special instructions

In the recommended dosage, the drug can be used for no more than 3 days without consulting a doctor.

Avoid getting the drug in the eyes.

Influence on the ability to drive vehicles and use mechanisms

The drug affects vision (if it gets into the eyes), the reaction rate may decrease.

In excess of the recommended dosages, it may affect the ability to drive a vehicle or equipment.

Name ENG

NESOPIN

Clinical and pharmacological group

A vasoconstrictor drug for local use in ENT practice

ATX code

Oxymetazoline

Dosage

0.05% x 20ml

Structure

Active ingredient: oxymetazoline hydrochloride - 0.5 mg

Excipients: menthol, eucalyptus oil, disodium edetate, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, propylene glycol, benzyl alcohol, water for injection up to 1 ml.

INN / Active ingredient

oxymetazoline hydrochloride

Storage conditions and periods

In a dark place at a temperature of 15-25 degrees.

Expiration date: 2 years

Specifications

Category

Runny nose

Scope of the drug

Ear, Throat, Nose

Release form

Spray

Manufacturer country

Russia

Package quantity, pcs

one

Scope of application

Virology

Minimum age from

6 years

Way of introduction

Intranasally

Vacation conditions

Without recipe

Volume, ml.

20 ml

Brand name

Synthesis

The amount of the dosage form in the primary package

20 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Decongestant - alpha adrenergic agonist

Anatomical and therapeutic characteristics

R01AA05 Oxymetazoline

Dosage form

Nasal spray

Dosage (volume) of the substance in the preparation

0.5 mg

Expiration date in days

730

The target audience

Children

Package weight, g

35

Mode of application

:

Nesopin is prescribed intranasally. < br> Adults and children over 12 years old - 2-3 injections into each nasal passage with an interval of 10-12 hours. < br> Children from 6 to 12 years old - 1 injection into each nasal passage.